GlaxoSmithKline plc: Will Its  Ongoing Investment In Oncology & Vaccines Pay Off? 

GlaxoSmithKline demonstrated robust quarterly performance, continuing its commitment to creating long-term value for its stakeholders. The company managed to deliver double-digit growth for the quarter, with sales increasing by 13% to GBP 7.4 billion, core operating profit going up by 35% to GBP 2.4 billion, and core earnings per share increasing by 37%. Underpinning GlaxoSmithKline’s solid financial results is the successful launch and strong delivery of its new products, reflecting the company’s ability to continue growing and innovating in the highly competitive pharmaceutical industry. The company is effectively leveraging its Research and Development (R&D) resources, leading to important advancements in its pipeline across various therapy areas.